TIMP-1

Summary

Gene Symbol: TIMP-1
Description: TIMP metallopeptidase inhibitor 1
Alias: CLGI, EPA, EPO, HCI, TIMP, TIMP-1, metalloproteinase inhibitor 1, collagenase inhibitor, erythroid potentiating activity, fibroblast collagenase inhibitor, tissue inhibitor of metalloproteinases 1
Species: human

Top Publications

  1. pmc Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study
    Jonas Hansson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e16185. 2011
  2. ncbi Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart
    Stephane Heymans
    CARIM, University Hospital Maastricht, Maastricht, The Netherlands
    Circulation 112:1136-44. 2005
  3. pmc Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway
    Veronica C Ardi
    Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 284:25854-66. 2009
  4. pmc Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation
    Yi Wang
    Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington 98195, USA
    J Biol Chem 282:31826-34. 2007
  5. pmc Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1
    Lisa A Ridnour
    Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    J Neurochem 123:736-49. 2012
  6. ncbi Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1
    Robert Ramer
    Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, Rostock D 18057, Germany
    J Natl Cancer Inst 100:59-69. 2008
  7. doi Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans
    B Meissburger
    Swiss Federal Institute of Technology, ETH Zurich, Institute for ETH Zürich, Food Nutrition and Health, Schorenstrasse 16, 8603 Schwerzenbach, Switzerland
    Diabetologia 54:1468-79. 2011
  8. ncbi Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1
    Meng Huee Lee
    Department of Oncology, Cancer Research UK Cambridge Research Institute, Cambridge University, Cambridge CB2 0RE, United Kingdom
    J Biol Chem 282:6887-98. 2007
  9. doi Integrin alphavbeta3-mediated transcriptional regulation of TIMP-1 in a human ovarian cancer cell line
    Dong Seok Kim
    National Research Laboratory, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 134 Sinchon Dong Seodaemun Gu, 120 749 Seoul, Republic of Korea
    Biochem Biophys Res Commun 377:479-83. 2008
  10. doi Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study
    Jonas Hansson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Eur J Cardiovasc Prev Rehabil 16:297-303. 2009

Research Grants

  1. Nancy Berliner; Fiscal Year: 2015
  2. Long-acting EPO analog for treating anemia associated with chronic kidney disease
    GEORGE NORBERT COX; Fiscal Year: 2010
  3. BMP4 dependent stress erythropoiesis pathway in short-term radioprotection
    ROBERT FRANK PAULSON; Fiscal Year: 2013
  4. Sandra E Juul; Fiscal Year: 2016
  5. Robin K Ohls; Fiscal Year: 2014
  6. Patrick J Heagerty; Fiscal Year: 2016
  7. Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome
    Alan F List; Fiscal Year: 2012
  8. A NOVEL ELECTROPORATION SYSTEM FOR GENE THERAPY WITH EPO
    MAIDA DE LAS ALAS; Fiscal Year: 2002
  9. Jianming Qiu; Fiscal Year: 2016
  10. Erythropoietin in Non-Erythroid Cells: Function and Regulation
    Josef T Prchal; Fiscal Year: 2013

Patents

  1. Process for the production of a protein

Detail Information

Publications353 found, 100 shown here

  1. pmc Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study
    Jonas Hansson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e16185. 2011
    ..An altered extracellular matrix metabolism has been implicated in a variety of diseases. We investigated relations of serum levels of MMP-9 and TIMP-1 to mortality risk from an etiological perspective.
  2. ncbi Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart
    Stephane Heymans
    CARIM, University Hospital Maastricht, Maastricht, The Netherlands
    Circulation 112:1136-44. 2005
    ..Whether their expression is related to interstitial fibrosis or LV dysfunction in patients with chronic pressure overload-induced LV hypertrophy, however, is unknown...
  3. pmc Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway
    Veronica C Ardi
    Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 284:25854-66. 2009
    ..activity of the generated MMP-9 enzyme were critically dependent on the tissue inhibitor of metalloproteinase (TIMP)-free status of the zymogen...
  4. pmc Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation
    Yi Wang
    Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington 98195, USA
    J Biol Chem 282:31826-34. 2007
    ..The N-terminal cysteine of TIMP-1 plays a key role in the inhibitory activity of the protein because it coordinates the essential catalytic Zn2+ of ..
  5. pmc Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1
    Lisa A Ridnour
    Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    J Neurochem 123:736-49. 2012
    ..Regulation of MMP-9 and its endogenous inhibitor tissue inhibitor of metalloproteinase (TIMP)-1 by nitric oxide (NO) has been shown...
  6. ncbi Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1
    Robert Ramer
    Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, Rostock D 18057, Germany
    J Natl Cancer Inst 100:59-69. 2008
    ..Although the antiproliferative activities of cannabinoids have been intensively investigated, little is known about their effects on tumor invasion...
  7. doi Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans
    B Meissburger
    Swiss Federal Institute of Technology, ETH Zurich, Institute for ETH Zürich, Food Nutrition and Health, Schorenstrasse 16, 8603 Schwerzenbach, Switzerland
    Diabetologia 54:1468-79. 2011
    ..differentiation and is controlled by the matrix metalloproteinase-tissue inhibitor of matrix metalloproteinase (TIMP) enzyme system...
  8. ncbi Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1
    Meng Huee Lee
    Department of Oncology, Cancer Research UK Cambridge Research Institute, Cambridge University, Cambridge CB2 0RE, United Kingdom
    J Biol Chem 282:6887-98. 2007
    ..There are four mammalian TIMPs (TIMP-1 to -4) but only TIMP-3 is sequestered to the extracellular matrix (ECM)...
  9. doi Integrin alphavbeta3-mediated transcriptional regulation of TIMP-1 in a human ovarian cancer cell line
    Dong Seok Kim
    National Research Laboratory, Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 134 Sinchon Dong Seodaemun Gu, 120 749 Seoul, Republic of Korea
    Biochem Biophys Res Commun 377:479-83. 2008
    ..effect of a disintegrin, saxatilin, on the balance between MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in human ovarian cancer cell line MDAH 2774...
  10. doi Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study
    Jonas Hansson
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Eur J Cardiovasc Prev Rehabil 16:297-303. 2009
    ..We hypothesized that circulating MMP-9 and TIMP-1 levels are altered already in persons with the signs of LV remodeling that forego clinical heart failure.
  11. ncbi Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease
    J Safranek
    Departments of Surgery, Faculty of Medicine in Pilsen, Charles University in Prague, University Hospital in Pilsen, Czech Republic
    Anticancer Res 29:2513-7. 2009
    The expression of matrix metallo-proteinases (MMP-7 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which are involved in the degradation of the extracellular matrix (ECM) and tumor growth, was investigated in ..
  12. doi Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer
    Marie Klintman
    Department of Oncology, Clinical Sciences, Barngatan 2B, Lund University, 221 85 Lund, Sweden
    Breast Cancer Res Treat 121:365-71. 2010
    In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is ..
  13. doi A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1
    Hans J Nielsen
    Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Scand J Gastroenterol 45:200-7. 2010
    ..purpose of this study was to assess the combination of preoperative serum carcinoembryonic antigen (CEA) and plasma tissue inhibitor of metalloproteinases (TIMP)-1 as a prognostic index in patients with primary, curatively resected CRC.
  14. doi Increased MMP-9 and TIMP-1 in mouse neonatal brain and plasma and in human neonatal plasma after hypoxia-ischemia: a potential marker of neonatal encephalopathy
    Nathalie Bednarek
    INSERM, Hopital Robert Debre, Paris, France
    Pediatr Res 71:63-70. 2012
    ..We evaluated the effectiveness of matrix metalloproteinases (MMPs) and their naturally occurring tissue inhibitors of metalloproteinases (TIMPs) in predicting neonatal encephalopathy (NE) damage in newborns...
  15. ncbi Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue
    B Brehmer
    Clinic of Urology, University Clinic Aachen, Germany
    Prostate Cancer Prostatic Dis 6:217-22. 2003
    ..The balance between the MMPs and their natural inhibitors (tissue inhibitors of matrix metalloproteinases; TIMP) seems to be an important factor related to this role...
  16. ncbi Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts
    Serena Fineschi
    Immunology and Allergy, Department of Internal Medicine, Geneva University Hospital, Geneva School of Medicine, Geneva, Switzerland
    FASEB J 20:562-4. 2006
    ..A dose- and time-dependent reduction in type-I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) production was observed in normal fibroblasts exposed to proteasome inhibitors (PI)...
  17. ncbi Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis
    Brigitte Bauvois
    INSERM 507, CNRS UMR 7131, Hopital Necker, Paris, France
    Nephrol Dial Transplant 22:1115-22. 2007
    Dysregulated renal expression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMP) and TGF-beta1 contribute to the development of tubulo-interstitial fibrosis characteristic of progressive forms of primary ..
  18. doi Human chorionic gonadotropin stimulates matrix metalloproteinases-2 and -9 in cytotrophoblastic cells and decreases tissue inhibitor of metalloproteinases-1, -2, and -3 in decidualized endometrial stromal cells
    Herbert Fluhr
    Department of Obstetrics and Gynecology, University of Greifswald, Greifswald, Germany
    Fertil Steril 90:1390-5. 2008
    ..To investigate the influence of hCG on trophoblastic matrix metalloproteinases (MMPs) -2 and -9 as well as endometrial tissue inhibitor of metalloproteinases (TIMPs) -1, -2, and -3...
  19. doi Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display
    Hyun Joo Ahn
    Daejon KRIBB Fred Hutchinson Cancer Research Center Research Cooperation Center, Korea Research Institute of Bioscience and Biotechnology, 52 Yuseong, Daejon 305 806, Republic of Korea
    J Biotechnol 151:225-30. 2011
    Aberrant glycosylation of human tissue inhibitor of metalloproteinase-1 (TIMP-1) by N-acetylglucosaminyltransferase-V (GnT-V) was previously reported to be related to cancer progression...
  20. ncbi Chromosomal assignment of the gene encoding the human tissue inhibitor of metalloproteinases to Xp11.1-p11.4
    N K Spurr
    Human Genetic Resources Laboratory, Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Herts
    Ann Hum Genet 51:189-94. 1987
    The tissue inhibitor of metalloproteinases (TIMP) is thought to play a regulatory role in connective tissues by forming inactive complexes with those metalloproteinases that are normally responsible for connective tissue turnover...
  21. ncbi Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells
    Jeong Ran Kim
    National Research Laboratory for Glycobiology, Ministry of Science and Technology and Department of Biochemistry and Molecular Biology, Dongguk University COM, Kyungbuk 780 714, South Korea
    Int J Biochem Cell Biol 36:2293-306. 2004
    ..Low levels of TIMP-1 and TIMP-3 were observed in HFH-T2, HepG2-HBV and Hep3B, while the TIMP-2 level was high, as evidenced by reverse ..
  22. ncbi The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracel
    T W Weiss
    Department of Internal Medicine II, Medical University of Vienna, Austria
    J Mol Cell Cardiol 39:545-51. 2005
    ..Here we show that TIMP-1 was upregulated up to threefold after treatment with the inflammatory mediator and gp130 ligand oncostatin M (OSM)..
  23. ncbi High level production of secreted proteins: example of the human tissue inhibitor of metalloproteinases 1
    L Crombez
    Groupe de Recherche et d Etude du Processus Inflammatoire, MENRT EA 2938, DBPC Enzymologie, Centre Hospitalier Universitaire de Grenoble, BP 217, 38043 Grenoble Cedex 9, France
    Biochem Biophys Res Commun 337:908-15. 2005
    ..We hereby propose a new method to overproduce human recombinant TIMP-1 by transient expression in HEK293E cells, followed by a one-step chromatography purification, yielding in only 2 ..
  24. ncbi Serum tissue inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial stiffness
    Mahmoud Zureik
    National Institute of Health and Medical Research INSERM, Unit 508, Lille, France
    J Hypertens 23:2263-8. 2005
    ..In a population-based study, we report the relationships of serum TIMP-1 with carotid intima-media thickness, carotid plaques and aortic arterial stiffness.
  25. ncbi TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein
    M E Taube
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Oncogene 25:3041-8. 2006
    Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can directly regulate cell growth and apoptosis independent of its matrix metalloproteinases (MMPs)-inhibitory activity...
  26. ncbi Suppression effects of human recombinant tissue inhibitor of metalloproteinases-1(TIMP-1) on tumor proliferation using in vivo treatment model of well-differentiated colon cancer cell line, HT29
    Yuu Ohtani
    Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700 8558, Japan
    Acta Med Okayama 60:257-66. 2006
    To investigate the suppressive effect of human recombinant TIMP-1 (rh-TIMP-1) on tumor proliferation using an in vivo xenograft system, HT29 was suspended in 0...
  27. ncbi Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression
    A O'Grady
    Department of Histopathology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland
    Histopathology 51:793-804. 2007
    To investigate the expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer (NMSC) and to compare their expression between different tumour types and ..
  28. doi Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction
    Antonios Halapas
    Department of Experimental Physiology, Medical School, University of Athens, Athens, Greece
    Clin Chem Lab Med 46:510-6. 2008
    ..concentrations of OPG and RANKL correlate with the serum levels of metalloproteinase-1 (MMP-1), MMP-9 and tissue inhibitors of MMP-1 (TIMP-1), which are known regulators of myocardial healing in acute myocardial infarction (AMI) patients.
  29. doi Bronchoalveolar lavage MMP-9 and TIMP-1 in preschool wheezers and their relationship to persistent wheeze
    Michel D S Erlewyn-Lajeunesse
    Allergy and Inflammation Sciences, University of Southampton, Southampton, UK
    Pediatr Res 64:194-9. 2008
    ..Protease-antiprotease balance between MMP-9 and its cognate inhibitor TIMP-1 may be involved in this process...
  30. ncbi Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer
    C Kahlert
    Institute of Pathology, University Hospital Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany
    Anticancer Res 28:1459-65. 2008
    ..The distribution of MMPs and TIMPs in the invasion front of liver metastases from colorectal cancer were investigated in order to understand their potential role in invasiveness...
  31. ncbi [Relationships between the expressions of intercellular adhesion molecule-1 and tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 in lung tissues of patients with chronic obstructive pulmonary disease]
    Ying jun Kong
    Department of Respiratory Medicine, The First Clinical College of Harbin Medical University, Harbin 150001, China
    Zhonghua Jie He He Hu Xi Za Zhi 31:129-33. 2008
    To evaluate the correlation between the expressions of intercellular adhesion molecule-1 (ICAM-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and matrix metalloproteinase-9 (MMP-9) in lung tissues of patients with COPD.
  32. doi Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis
    J C C Wei
    Department of Medicine, Chung Shan Medical University, Taichung, Taiwan
    Ann Rheum Dis 68:1781-6. 2009
    ..Fibrosis results from excessive accumulations of the extracellular matrix (ECM). ECM turnover depends on the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs)...
  33. doi Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents
    Vanessa A Belo
    Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 13081 970 Campinas, SP, Brazil
    Clin Biochem 42:984-90. 2009
    ..pro-MMP-2, pro-MMP-9, and total MMP-9, their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-2, and the MMP-8/TIMP-1, MMP-9/TIMP-1, and MMP-2/TIMP-2 ratios in normotensive obese children and ..
  34. doi TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles
    Hanne Offenberg
    Department of Veterinary Pathobiology, Section of Biomedicine, Faculty of Life Sciences, University of Copenhagen, DK 1870 Frederiksberg C, Denmark
    Mol Oncol 2:233-40. 2008
    ..shown that colorectal cancer patients have increased plasma levels of the tissue inhibitor of metalloproteinases-1 (TIMP-1), and that high plasma TIMP-1 levels are associated with short colorectal cancer patient survival...
  35. pmc Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion
    Anitha S John
    Children s Hospital of Philadelphia, Department of Pediatric Cardiology, Philadelphia, PA 19104, USA
    Exp Mol Pathol 87:184-8. 2009
    ..We now report that TSP-1 up-regulates TIMP-1 expression in both human breast and prostate cancer cell lines...
  36. doi mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor
    Carlos Alberto Scrideli
    Department of Pediatrics, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    Leuk Res 34:32-7. 2010
    ..04) and multivariable analysis (P=0.01). Our data address new information in the complex interaction of the migration/adhesion genes and childhood ALL...
  37. pmc Mechanism of heparin acceleration of tissue inhibitor of metalloproteases-1 (TIMP-1) degradation by the human neutrophil elastase
    Gabriel L C Nunes
    Centro Interdisciplinar de Investigação Bioquímica, Universidade de Mogi das Cruzes, Mogi das Cruzes, Brazil
    PLoS ONE 6:e21525. 2011
    ..We have assessed the regulatory effect of heparin on Tissue Inhibitor of Metalloproteases-1 [TIMP-1] hydrolysis by HNE employing the recombinant form of TIMP-1 and correlated FRET-peptides comprising the TIMP-1 ..
  38. pmc Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
    Volkmar Muller
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20241 Hamburg, Germany
    Breast Cancer Res 13:R71. 2011
    ..The tissue inhibitor of metalloproteinase 1 (TIMP-1) plays a role in tissue invasion and is also involved in angiogenesis, abrogation of apoptosis and in ..
  39. pmc Expression of MMP-2 and TIMP-1 in renal tissue of patients with chronic active antibody-mediated renal graft rejection
    Qiang Yan
    Dialysis and Kidney Transplantation Center of PLA, 181 Hospital of PLA, Guilin 541002, China
    Diagn Pathol 7:141. 2012
    To investigate the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metallopropteinase-1 (TIMP-1) in the renal allografts of patients with chronic active antibody-mediated rejection (AMR), and to explore their role ..
  40. doi Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1
    Zeng Feng Xin
    Department of Orthopedic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, PR China
    Int J Mol Med 31:105-12. 2013
    ..MMPs) play critical roles in invasion and metastasis, and the tissue inhibitors of metalloproteinase (TIMP) family regulates the activity of multifunctional metalloproteinases...
  41. pmc Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis
    N Katoh
    Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Clin Exp Immunol 127:283-8. 2002
    ..examined the role of TIMPs and MMPs in the pathogenesis of atopic dermatitis (AD) by evaluating the serum levels of TIMP-1 and MMP-3 in 40 patients with AD and 20 control subjects by ELISA...
  42. ncbi Increased backbone mobility in beta-barrel enhances entropy gain driving binding of N-TIMP-1 to MMP-3
    S Arumugam
    Department of Biochemistry, University of Missouri, 117 Schweitzer Hall, Columbia, MO 65211, USA
    J Mol Biol 327:719-34. 2003
    The high-affinity inhibition of stromelysin 1 (MMP-3) by tissue inhibitor of metalloproteinases 1 (TIMP-1) helps control tissue remodeling and tumor development...
  43. ncbi Global orientation of bound MMP-3 and N-TIMP-1 in solution via residual dipolar couplings
    S Arumugam
    Department of Biochemistry, 117 Schweitzer Hall, University of Missouri, Columbia, Missouri 65211, USA
    Biochemistry 42:7950-8. 2003
    Crystal structures of catalytic domains of MMP-3 and MT1-MMP bound to TIMP-1 or TIMP-2, respectively, differ in the orientation of the TIMP in the MMP active site...
  44. pmc Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
    Raymond Lai
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Am J Pathol 164:2251-8. 2004
    ..TIMP1, as a downstream target of STAT3, may mediate the anti-apoptotic effects of STAT3...
  45. pmc Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer
    Jennifer Dien
    Department of Laboratory Medicine and Pathology, University of Alberta, 4B1, 8440 112 St, Edmonton, Alberta, Canada
    Am J Pathol 169:633-42. 2006
    ..We have previously shown that STAT3 up-regulates tissue inhibitors of metalloproteinase (TIMP)-1, a cytokine known to block metalloproteinases and decrease invasiveness in certain cancer cell types...
  46. pmc Matrix metalloproteinase-3 promoter polymorphisms but not dupA-H. pylori correlate to duodenal ulcers in H. pylori-infected females
    Yi Chun Yeh
    Institute of Clinical Medicine, National Cheng Kung University Hospital, Medical College, Tainan, Taiwan
    BMC Microbiol 10:218. 2010
    ..host single nucleotide polymorphisms (SNPs) of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), including MMP-3, MMP-7, MMP-9, TIMP-1 and TIMP-2, might correlate with ulcer risk of H. pylori-infected Taiwanese patients.
  47. ncbi Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis
    Frank R Murphy
    Liver Group, Division of Infection, Inflammation and Repair, University of Southampton, Hampshire SO16 6YD, United Kingdom
    J Biol Chem 277:11069-76. 2002
    ..to liver fibrosis as the major source of collagens I and III and the tissue inhibitors of metalloproteinase-1 (TIMP-1)...
  48. pmc Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease
    Brian C McKaig
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, United Kingdom
    Am J Pathol 162:1355-60. 2003
    ..mucosal samples there is significantly higher constitutive expression of tissue inhibitor of metalloproteinase (TIMP)-1 compared to similar cells isolated from normal or ulcerative colitis tissue...
  49. ncbi Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model
    Yasuhide Ikenaka
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Int J Cancer 105:340-6. 2003
    The tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) has been recognized as a multifunctional protein...
  50. ncbi Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus
    Cristiana Matache
    Department of Immunology, Cantacuzino National Institute of Research, Splaiul Independentei 103, Bucharest R 70 100, Romania
    J Autoimmun 20:323-31. 2003
    ..MMP-9 and MMP-9 mRNA levels in peripheral blood mononuclear cells (PBMCs), the spontaneous secretion of MMP-9 and TIMP-1 and the MMP-9 activity...
  51. pmc Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia
    Radhika Suryadevara
    Laboratory of Cellular Neuroimmunology, Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
    Glia 44:47-56. 2003
    ..We hypothesized that in response to injury and inflammation in HAD, astrocytes regulate the production of TIMP-1, the inducible type of TIMP that is important in inflammation...
  52. ncbi Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms
    Dietmar Krex
    Department of Neurosurgery, University Hospital Carl Gustav Carus, University of Technology, Dresden, Germany
    Stroke 34:2817-21. 2003
    ..Their activity is controlled predominantly by tissue inhibitors of metalloproteinases (TIMPs). To investigate the possible impact of genetic variants within the genes encoding TIMP-1, -2, and -3, we conducted this case-control study.
  53. ncbi Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival
    William Hornebeck
    Laboratoire de Biochimie, Faculte de Medecine, IFR53 Biomolecules, Centre National de la Recherche Scientifique CNRS FRE 2534, Universite de Reims Champagne Ardenne, 51, rue Cognacq Jay, 51095 Reims, France
    Pathol Biol (Paris) 51:569-73. 2003
    ..Tissue inhibitor of metalloproteinase-1 (TIMP-1) is one representative of the natural MMP inhibitor family, encompassing four members...
  54. pmc Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system
    Jessica Gardner
    Laboratory of Cellular Neuroimmunology, Center for Neurovirology and Neurodegenerative Disorders, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 5215, USA
    J Neurosci Res 74:801-6. 2003
    ..Recently, TIMP-1, the inducible form, has been identified as a multifunctional molecule with divergent functions...
  55. ncbi TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src
    Seo Jin Lee
    Department of Biochemistry, College of Science, and Protein Network Research Center, Yonsei University, Seoul, Republic of Korea
    Biochem Biophys Res Commun 312:1196-201. 2003
    In addition to inhibiting matrix metalloproteinases, tissue inhibitor of metalloproteinase-1 (TIMP-1) is involved in the regulation of cell growth and survival...
  56. pmc Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity
    Alicja Wiercinska-Drapalo
    Department of Infectious Diseases, Intestinal Diseases Unit, Medical University of Bialystok, 15 540 Bialystok, Zurawia str, 14, Poland
    World J Gastroenterol 9:2843-5. 2003
    ..Their activity can be counterbalanced by the tissue inhibitor of metalloproteinases (TIMP)...
  57. ncbi TIMP-1 alters susceptibility to carcinogenesis
    Jin Sae Rhee
    Medical Scientist Training Program, Cancer Research Institute, University of California, San Francisco, California, USA
    Cancer Res 64:952-61. 2004
    ..Elevated mRNA expression of TIMP family members correlates with malignancy and clinical outcome in many human cancer types; however, a protective ..
  58. ncbi Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer
    Anne Sofie Schrohl
    The Royal Veterinary and Agricultural University, Department of Pharmacology and Pathobiology, Frederiksberg C, Denmark
    Clin Cancer Res 10:2289-98. 2004
    ..study, we investigated the association between tumor tissue levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prognosis in patients with primary breast cancer and analyzed whether TIMP-1 may be useful as a prognostic ..
  59. ncbi Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent
    Valerie Gouyer
    Unité INSERM 560, Place de Verdun, Lille, France
    Cancer 103:1676-84. 2005
    ..In this study, mRNA expression levels of MMP-1, MMP-9, TIMP-1, and TIMP-2 were evaluated in patients with resected NSCLC, and their associations with disease progression and ..
  60. ncbi Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment
    C Avolio
    Department of Medical and Occupational Sciences, University of Foggia, Foggia, Italy
    Mult Scler 11:441-6. 2005
    ..We studied the relationships between serum MMP-9, MMP-2, TIMP-1 and TIMP-2 and different magnetic resonance imaging (MRI) measures of disease activity in MS patients during ..
  61. pmc A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women
    F Lose
    Asthma and Allergy Research Institute, QEII Medical Centre, Nedlands, WA 6009, Australia
    Thorax 60:623-8. 2005
    ..airway imbalance between levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) is associated with airway remodelling...
  62. ncbi Potential mechanisms for astrocyte-TIMP-1 downregulation in chronic inflammatory diseases
    Jessica Gardner
    Laboratory of Cellular Neuroimmunology, Center for Neurovirology and Neurodegenerative Disorders, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198 5215, USA
    J Neurosci Res 83:1281-92. 2006
    ..In the context of disease, TIMP-1 has emerged as an important multifunctional protein capable of regulating inflammation...
  63. pmc Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein
    Ki Kyung Jung
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
    EMBO J 25:3934-42. 2006
    This study identified CD63, a member of the tetraspanin family, as a TIMP-1 interacting protein by yeast two-hybrid screening...
  64. pmc Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer
    F J G M Kubben
    Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
    Br J Cancer 95:744-51. 2006
    ..Single-nucleotide polymorphisms (SNPs) in MMP and TIMP genes may be associated with disease susceptibility and might also affect their antigen expression...
  65. ncbi A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes
    Katarzyna M Wilczynska
    Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298, USA
    J Biol Chem 281:34955-64. 2006
    ..In astrocytes, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) is up-regulated by interleukin-1 (IL-1), which is a major neuroinflammatory cytokine...
  66. ncbi Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer
    Anne Sofie Schrohl
    Department of Veterinary Pathobiology, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
    Clin Cancer Res 12:7054-8. 2006
    ..Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been shown to protect against apoptosis, and the purpose of the present study was to test the hypothesis ..
  67. ncbi Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state
    Konstantinos Aznaouridis
    Atherosclerosis 195:212-5. 2007
  68. ncbi TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid
    Nanna M Sørensen
    Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark
    Clin Cancer Res 13:4117-22. 2007
    Tissue inhibitor of metalloproteinase-1 (TIMP-1) is known to protect cells against apoptosis...
  69. pmc Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors
    Asmaa B Hamze
    College of Biomedical Science, Florida Atlantic University, Boca Raton, Florida 33431, USA
    Protein Sci 16:1905-13. 2007
    ..Since unregulated MMP activities are linked to arthritis, cancer, and atherosclerosis, TIMP variants that are selective inhibitors of disease-related MMPs have potential therapeutic value...
  70. ncbi Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study
    Sidse Ørnbjerg Würtz
    Department of Veterinary Pathology, The Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, DK 1870 Frederiksberg C, Denmark
    Mol Cell Proteomics 7:424-30. 2008
    The tumor level of TIMP-1 has been suggested as a new prognostic marker in breast cancer...
  71. doi Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1
    Hua Liu
    Vascular Biology Center, Department of Obstetrics and Gynecology, Medical College of Georgia, 1459 Laney Walker Blvd, Augusta, GA 30912, USA
    Angiogenesis 11:223-34. 2008
    ..Interestingly, we identified tissue inhibitor of metalloproteinase-1 (TIMP-1) as a factor uniquely secreted by fibroblasts, and addition of exogenous TIMP-1 increased vessel assembly...
  72. doi A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer
    Anne Sofie Schrohl
    Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark
    Tumour Biol 29:181-7. 2008
    Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer...
  73. doi TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro
    Rebecca L H Bigelow
    Department of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, 71130, USA
    Breast Cancer Res Treat 117:31-44. 2009
    b>TIMP-1 (Tissue inhibitor of matrix metalloproteinase-1) is typically associated with inhibition of matrix metalloproteinases (MMP) induced invasion...
  74. doi Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival
    Charlotte Aaberg-Jessen
    Department of Pathology, Odense University Hospital, Odense, Denmark
    J Neurooncol 95:117-28. 2009
    In colorectal cancer and breast cancer a high TIMP-1 level has been shown to correlate with a shorter overall patient survival and it has been suggested that TIMP-1 is involved in tumour invasion, proliferation and apoptosis in different ..
  75. doi Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1
    Ting Wang
    Nanjing Medical University, China
    Int J Cancer 126:362-70. 2010
    ..Tissue inhibitor of metalloproteinase-1 (TIMP-1) is well known to be capable of inhibiting apoptosis...
  76. doi Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor
    Barbara Mroczko
    Department of Biochemical Diagnostics, Medical University, Bialystok, Poland
    Pancreas 38:613-8. 2009
    ..The aim of the study was to determine the diagnostic and prognostic significance of the measurements of serum MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with PC.
  77. doi High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents
    Evangelos Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, 5 Marathonomahon Street, 14572 Drosia, Athens, Greece
    Leuk Res 34:399-402. 2010
    Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma...
  78. pmc Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction
    Patricia L Jackson
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Mol Med 16:159-66. 2010
    ..both direct MMP-9 activation and the degradation of its natural inhibitor, tissue inhibitor of metalloprotease-1 (TIMP-1)...
  79. doi Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers
    Saher B Shaker
    Department of Cardiology and Respiratory Medicine, Hvidovre University Hospital, Copenhagen, Denmark
    Clin Respir J 2:17-25. 2008
    ..Inflammation is an important constituent of the pathology of chronic obstructive pulmonary disease (COPD), leading to alveolar destruction and airway remodelling...
  80. doi Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma
    Nicholas J Clemons
    Medical Research Council Cancer Cell Unit, Hutchison Medical Research Council Centre, Hills Road, Cambridge, CB2 0XZ, UK
    Carcinogenesis 31:1669-75. 2010
    ..expression of matrix metalloproteinase (MMP)-1, -3, -7, -9 and -10 and tissue inhibitor of metalloproteinase (TIMP)-1, -2 and -3 in these cell lines...
  81. doi TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis
    Ioanna Tsagaraki
    Institute of Biology, National Center for Scientific Research Demokritos, 15310 Agia Paraskevi, Athens, Greece
    Cell Tissue Res 342:87-96. 2010
    ..Our data showed that resistance to apoptosis was accompanied by high levels of TIMP-1 expression in part mediated by NF-κB activation, whereas under apoptotic conditions, in the presence of ..
  82. pmc Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor
    Matthew Crocker
    Academic Neurosurgery Unit, Room 1 122 Jenner Wing, St George s University of London, Cranmer Terrace, Tooting, London SW17 0RE
    Neuro Oncol 13:99-108. 2011
    ..Tumor samples were also immunostained for tissue inhibitor of metalloproteinase-1 (TIMP-1). Cluster analysis of the serum angiogenic profiles revealed 2 distinct subtypes of glioblastoma...
  83. pmc Plasma markers for identifying patients with metastatic melanoma
    Harriet M Kluger
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 17:2417-25. 2011
    ..Our purpose was to study levels of proteins that might be secreted in the blood of patients with metastatic melanoma that can be used for monitoring these individuals...
  84. doi Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway
    Z Y Fu
    Department of Cell Biology and Medical Genetics, Nanjing Medical University, Nanjing 210029, China
    Biomed Pharmacother 65:163-7. 2011
    b>TIMP-1 is well known to be capable of inhibiting apoptosis. Elevated levels of TIMP-1 in tumor tissue have been shown to be strongly associated with a poor response to chemotherapy...
  85. doi BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy
    Alessandra Bommarito
    Sezione di Endocrinologia, Laboratorio di Endocrinologia Molecolare, Dipartimento di Biomedico di Medicina Interna e Specialistica DIBIMIS, University of Palermo, Italy
    Endocr Relat Cancer 18:669-85. 2011
    ..Tissue inhibitor of metalloproteinases (TIMP-1) and nuclear factor (NF)-κB have been shown to play an important role in thyroid cancer...
  86. doi Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells
    Antonia Patruno
    Department of Drug Sciences, University G D Annunzio, Chieti, Italy
    J Cell Physiol 227:2767-74. 2012
    ..We then analyzed the role of nitration of TIMP-1 in increasing the activity of MMPs in EMF exposed cells...
  87. pmc Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling
    Virginia Egea
    Division of Clinical Chemistry and Clinical Biochemistry, Surgical Department, Ludwig Maximilians University, 80336 Munich, Germany
    Proc Natl Acad Sci U S A 109:E309-16. 2012
    b>Tissue inhibitor of metalloproteinases 1 (TIMP-1) is a matrix metalloproteinase (MMP)-independent regulator of growth and apoptosis in various cell types...
  88. doi Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases
    Alessandro Neri
    Department of Human Pathology and Oncology, University of Siena, 53100 Siena, Tuscany, Italy
    Hum Pathol 43:1184-91. 2012
    ..Thus, tissue inhibitor of metalloproteinase-1 may have a role in clinical practice as a prognostic and predictive factor and a possible target for future therapies...
  89. pmc Tissue inhibitor of metalloproteinases-1 protects human neurons from staurosporine and HIV-1-induced apoptosis: mechanisms and relevance to HIV-1-associated dementia
    - Ashutosh
    Department of Cell Biology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
    Cell Death Dis 3:e332. 2012
    ..HAD)-relevant proinflammatory cytokines robustly induce astrocyte tissue inhibitor of metalloproteinases-1 (TIMP-1)...
  90. pmc Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression
    Yong Sam Kim
    Cancer Biomarkers Development Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak ro, Yuseong Gu, Daejeon, South Korea
    J Biol Chem 287:32467-78. 2012
    There has been ongoing debate over whether tissue inhibitor of metalloproteinase-1 (TIMP-1) is pro- or anti-oncogenic...
  91. ncbi Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease
    M Axel Wollmer
    Division of Psychiatry Research, University of Zurich, Switzerland
    Psychiatr Genet 12:155-60. 2002
    b>Tissue inhibitor of metalloproteinases 1 (TIMP-1) inhibits several proteinases including a disintegrin and metalloproteinase 10 (ADAM10), a major alpha-secretase that cleaves the beta-amyloid precursor protein within its amyloidogenic ..
  92. ncbi Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway
    Xu Wen Liu
    Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Biol Chem 278:40364-72. 2003
    Tissue inhibitor of metalloproteinase (TIMP-1) is a natural protease inhibitor of matrix metalloproteinases (MMPs). Recent studies revealed a novel function of TIMP-1 as a potent inhibitor of apoptosis in mammalian cells...
  93. ncbi Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein
    Henni Ruokolainen
    Department of Oncology, University of Oulu and Oulu University Hospital, Oulu, Finland
    Clin Cancer Res 11:3257-64. 2005
    Tissue inhibitors of metalloproteinases (TIMP) are capable of inhibiting the matrix metalloproteinases, but they also possess other biological functions...
  94. ncbi Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress
    Krystyna Pawlak
    Department of Nephrology and Transplantology, Medical University of Białystok, 14 Zurawia Street, 15 540 Białystok, Poland
    Cytokine 31:18-24. 2005
    ..We compared pre-dialysis levels of MMP-9/TIMP-1 system, beta-chemokines, Cu/Zn superoxide dismutase (Cu/Zn SOD) as a marker of SOX and C-reactive protein (CRP) ..
  95. pmc Novel role of TGF-beta in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and neuroinflammation
    Alok Dhar
    Laboratory of Cellular Neuroimmunology, University of Nebraska Medical Center, Omaha, Nebraska 68198 5215, USA
    J Neurosci Res 83:1271-80. 2006
    Astrocyte production of tissue inhibitor of metalloproteinase (TIMP)-1 is important in central nervous system (CNS) homeostasis and inflammatory diseases such as HIV-1-associated dementia (HAD)...
  96. pmc Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis
    Ying De Wang
    Department of Gastroenterology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
    World J Gastroenterol 12:6050-3. 2006
    To examine the expression of metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the colonic mucosa of patients with ulcerative colitis (UC).
  97. ncbi Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis
    Martina Montagnana
    Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Ospedale Policlinico G B Rossi, Piazzale Scuro, 10, Verona, Italy
    Clin Biochem 40:837-42. 2007
    ..This activity is controlled by tissue inhibitors of MMP (TIMPs). Aim of this study was the evaluation of MMP-9/TIMP-1 and MMP-2/TIMP-2 systems in patients with SSc.
  98. ncbi Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2
    Jean Luc Brun
    Departments of Gynecology, AP HP, Hopital Tenon, 4 rue de la Chine, F 75571 Paris Cedex, France
    Int J Oncol 33:1239-46. 2008
    ..This study aimed to evaluate the immunohistochemical expression of MMP-2, -7, -9, MT1-MMP, TIMP-1 and -2 in these tumors...
  99. doi Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer
    Takaki Yoshikawa
    Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1 1 2 Nakao, Asahi ku, Yokohama, 241 0815, Japan
    Gastric Cancer 12:31-6. 2009
    The expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) is correlated with tumor invasion and metastases.
  100. pmc TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 10:139. 2010
    ..The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis...
  101. doi Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc
    Jacqueline Frost
    Division of Rheumatology, Faculty of Health Sciences, Chris Hani Baragwanath Academic Hospital, P O Bertsham 2013, South Africa
    Rheumatology (Oxford) 51:1049-52. 2012
    To investigate the differential expression of MMP-1, tissue inhibitor of metalloproteinase-1 (TIMP-1) and hepatocyte growth factor (HGF) in clinically involved (affected) and uninvolved (unaffected) skin in patients with SSc.

Research Grants79

  1. Nancy Berliner; Fiscal Year: 2015
    ..we will investigate whether vitamin D and/or ?-3 FA influence erythropoiesis via hepcidin- and/or erythropoietin (EPO)-dependent pathways...
  2. Long-acting EPO analog for treating anemia associated with chronic kidney disease
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..Anemia typically results from inability of the diseased kidney to produce erythropoietin (EPO), which stimulates production of red blood cells...
  3. BMP4 dependent stress erythropoiesis pathway in short-term radioprotection
    ROBERT FRANK PAULSON; Fiscal Year: 2013
    ..suggests that the primary therapies for anemia, transfusion therapy and treatment with recombinant erythropoietin (Epo), can themselves cause pathology...
  4. Sandra E Juul; Fiscal Year: 2016
    ..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
  5. Robin K Ohls; Fiscal Year: 2014
    ..One promising intervention is the use of recombinant erythropoietin (Epo, also known as an erythropoiesis stimulating agent, or ESA)...
  6. Patrick J Heagerty; Fiscal Year: 2016
    ..New approaches are needed to improve these outcomes. Recombinant erythropoietin (Epo) is a promising novel neuroprotective agent...
  7. Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome
    Alan F List; Fiscal Year: 2012
    ..challenge in MDS with only a minority of patients experiencing sustained benefit from recombinant erythropoietin (EPO)...
  8. A NOVEL ELECTROPORATION SYSTEM FOR GENE THERAPY WITH EPO
    MAIDA DE LAS ALAS; Fiscal Year: 2002
    ..Anemia is currently treated with repeated administration of recombinant erythropoietin (EPO), which is expensive and not readily available to these patients due to the already elevated cost of treatment for ..
  9. Jianming Qiu; Fiscal Year: 2016
    ..and fetal liver), and a reverse genetics approach that involves transfection of the B19V dsDNA-form genome into UT7/Epo-S1 cell line cells cultured under hypoxic conditions...
  10. Erythropoietin in Non-Erythroid Cells: Function and Regulation
    Josef T Prchal; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): PROJECT SUMMARY/ABSTRACT Erythropoietin (Epo) is the principle regulator of red cell production, as it controls the survival, proliferation, and differentiation of erythroid progenitors...
  11. TSAD AS AN EPOR/JAK2 ADAPTOR AND ERYTHROPOIETIC REGULATOR
    DONALD JOSEPH MCCRANN; Fiscal Year: 2010
    ..b>EPO is a key regulator of erythroid cell formation in response to hypoxia and anemia...
  12. VEGF Regulation of Hepatic Erythropoietin Synthesis
    Calvin Kuo; Fiscal Year: 2009
    ..of red blood cells (RBCs), is regulated by an intricate network of signals involving the hormone erythropoietin (Epo), and sensing of hypoxia through inhibition of both HIF-1alpha proline hydroxylation and its subsequent interaction ..
  13. SIGNAL TRANSDUCTION MECHANISMS OF ERYTHROPOIETIN
    Barbara A Miller; Fiscal Year: 2011
    The erythropoietin (Epo) receptor is a model for understanding signal transduction mechanisms of the cytokine receptor superfamily...
  14. Novel Erythroid Cell Membrane Protein
    Emery H Bresnick; Fiscal Year: 2010
    While erythropoietin (Epo) is commonly used to treat anemia in patients with cancer and kidney disease, recent studies have raised major safety concerns...
  15. Characterization of a Novel Erythropoietin Signaling Pathway
    Adam N Goldfarb; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The soluble cytokine erythropoietin (Epo) plays a central role in physiologic erythropoiesis and is a mainstay in treatment of human anemias...
  16. David Kuhrt; Fiscal Year: 2015
    ..In chronic disease settings, these bouts often become compromised. Clinically, recombinant human erythropoietin (EPO) and erythropoiesis stimulating agents (ESAs) are used to enhance red cell production during anemia, but are ..
  17. Erythropoietin Blockade for the Treatment of Cancer
    C Anthony Blau; Fiscal Year: 2012
    ..Erythropoietin (Epo) is the biggest drug in all of oncology...
  18. Molecular Analysis of the Erythropoietic Stress Response in vivo
    Merav Socolovsky; Fiscal Year: 2010
    ..Further, chronic stress in mice or acute Epo administration result in down-regulation of Fas and FasL from the early erythroblast cell surface...
  19. Multi-level analysis of iron metabolism and treatment of chronic kidney disease
    Paul L Fox; Fiscal Year: 2013
    ..Treatment of anemia in CKD patients by intravenous injection of iron and erythropoietin (Epo) in combination with dialysis, significantly improves results...
  20. Frank S Lee; Fiscal Year: 2014
    ..The prototypical HIF target gene is that encoding for Erythropoietin (EPO), a glycoprotein hormone that regulates red blood cell mass in response to changes in oxygen tension...
  21. Tonia S Rex; Fiscal Year: 2016
    ..We offer an alternative IOP-independent neuroprotective therapy, a modified form of erythropoietin (EPO). EPO is already FDA approved for the treatment of anemia...
  22. KUZHALI MUTHUMALAIAPPAN; Fiscal Year: 2016
    ..Reduced erythrocyte production due to lack of erythropoietin (Epo) could contribute to anemia...
  23. Mechanisms of tumor resistance to anti-HER/ErbB therapeutics
    Zhen Fan; Fiscal Year: 2012
    ..In this proposal, we will explore whether erythropoietin (EPO)-induced cell signaling plays a role in breast cancer resistance to trastuzumab...
  24. DON MICHAEL WOJCHOWSKI; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Important new actions of erythropoietin (EPO) are increasingly being realized in the contexts of ischemic cytoprotection, angiogenesis, thrombosis and the anemia of cancer and chemotherapy...
  25. JOSEPH ANTHONY GARCIA; Fiscal Year: 2016
    ..over the past several decades, almost all current therapies involve bolus administration of erythropoietin (epo), an endocrine factor produced in the adult kidney and also in the liver with severe anemia...
  26. Synthesis of a homogenous erythropoietin via iterative native chemical and alanin
    PAUL ANTHONY VADOLA; Fiscal Year: 2013
    ..Erythropoietin (EPO) is a naturally occurring hormone that is responsible for these tasks...
  27. Mechanisms of Neonatal Erythropoietin Neuroprotection
    Shenandoah Robinson; Fiscal Year: 2011
    ..Erythropoietin (EPO) and its cognate receptor EPOR are required for prenatal brain development, especially in the second half of ..
  28. Erythropoietin-encoding mRNA for treatment of anemia
    Katalin Kariko; Fiscal Year: 2010
    ..in this Fast-track proposal to develop the first of these therapeutic vectors for delivery of human erythropoietin (EPO)...
  29. Frank Pajonk; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): This study explores if radiation and erythropoietin (Epo) synergize to alter the self-renewal of breast cancer stem cells (BCSCs) and to reprogram differentiated breast cancer (BC) cells into induced ..
  30. Michael L Merchant; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Erythropoietin (EPO) and erythropoiesis-stimulating agents (ESAs) are used to treat the anemia of chronic renal disease in greater than 90% of all in-center hemodialysis patients at a cost of ..
  31. THE ROLE OF INFLAMMATION IN ANEMIA OF THE ELDERLY
    Tomas Ganz; Fiscal Year: 2010
    ..We propose that ADI is a state of relative resistance to erythropoietin (EPO) due to inflammation-induced restriction of iron supply to the bone marrow...
  32. Soluble EPO Receptor and EPO Resistance in Dialysis
    Ravi Thadhani; Fiscal Year: 2012
    ..This proposal has the potential to lead to changes in the diagnosis and management of patients with erythropoietin resistance. ..
  33. De-SUMOylation and the Hypoxic Response
    Edward T H Yeh; Fiscal Year: 2013
    ..lethality in mid- gestation in mice as a result of severe fetal anemia stemming from deficient erythropoietin (Epo) production...
  34. Mitochondrial Injury in the Anemia of Chronic Kidney Disease
    Madhumathi Rao; Fiscal Year: 2010
    ..Anemia is a common complication among patients with chronic kidney disease (CKD) and traditionally erythropoietin (EPO) deficiency has been considered the major cause...
  35. Grant C Bullock; Fiscal Year: 2014
    ..RESEARCH PLAN: Erythropoietin (Epo) is an essential cytokine for efficient red blood cell (rbc) production...
  36. Anna Rita F Migliaccio; Fiscal Year: 2015
    ..EB) maturation observed in patients with Diamond Blackfan Anemia (DBA), a congenic form of erythropoietin (EPO) resistant erythroid aplasia often associated with mutations that result in ribosome insufficiency...
  37. EMILY BARBARA COHEN; Fiscal Year: 2014
    ..and serious side effect of cancer-chemotherapy, which is often treated with recombinant human erythropoietin (EPO) to increase red blood cell production...
  38. The Intra-renal Oxygenation in CKD as evaluated by BOLD MRI
    Pottumarthi V Prasad; Fiscal Year: 2010
    ..commonly associated with anemia and it is believed to be related to reduced or lack of increase in erythropoietin (EPO) production. This in turn is believed to be due to enhanced renal cortical oxygen levels...
  39. Serpil C Erzurum; Fiscal Year: 2016
    ..18F- fluoro-deoxy-glucose analogue - positron emission tomography (FDG-PET), high-levels of plasma erythropoietin (Epo) and mobilization of bone marrow progenitors] are present in patients and quantitatively associated with PAP...
  40. AKT Signaling and Oxidative Stress Regulation of Erythropoiesis
    Saghi Ghaffari; Fiscal Year: 2013
    ..Signals generated from Erythropoietin (Epo) binding to its receptor erythropoietin receptor (EpoR) are mediated by JAK2 tyrosine kinase and are essential for ..
  41. FERNANDO FRANCISCO GONZALEZ; Fiscal Year: 2015
    ..a major role in brain development;(2) to determine the effects of neonatal stroke and exogenous erythropoietin (EPO) treatment on cell signaling, cell fate, and functional outcome;(3) to gain expertise in basic neurobiology and ..
  42. Human Milk Factor Protection in Neonatal Necrotizing Enterocolitis
    Sheng Ru Shiou; Fiscal Year: 2012
    ..The objective of this study is to investigate whether the human milk factors erythropoietin (Epo) and transforming growth factor-beta (TGF-b) have protective effects against NEC and to study the underlying ..
  43. PETER J HEINZELMAN; Fiscal Year: 2014
    ..neurotrophic factors, particularly granulocyte macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO), for increased BBB-traversal and neurotrophic activity duration...
  44. Connie C W Hsia; Fiscal Year: 2014
    ..has not been established, but the hypoxia-inducible factor-erythropoietin-vascular endothelial growth factor (HIF-EPO- VEGF) axis is implicated...
  45. Preoperative Therapy for Prevention of Postoperative Low Cardiac Output Syndrome
    D Woodrow Benson; Fiscal Year: 2010
    ..whether preoperative administration of glucocorticoids (methylprednisolone, steroids) and/or erythropoietin (EPO) will afford protection from ischemia-reperfusion injury and thereby reduce the incidence of LCOS for infants ..
  46. Erythropoietin PLUS IGF-IN NEUROPROTECTION FROM AIDS
    Stuart Lipton; Fiscal Year: 2009
    ..In attempting to prevent this type of HIV-related neurotoxicity, we discovered that erythropoietin (EPO), normally thought to be a kidney-generated cytokine, is made in the brain and is neuroprotective...
  47. LILY JUNSHEN HUANG; Fiscal Year: 2016
    ..These results will also further our understanding of how Epo signaling is terminated, and will shift the paradigm of how JAK2 activates erythroid transcriptional network...
  48. Ming Chang Hu; Fiscal Year: 2015
    ..HIF1/2 activation protects the kidney from IRI. Erythropoietin (EPO) has also been used for treatment of ischemic injury in the brain, heart, and kidney...
  49. EXPERIMENTAL DIABETIC AUTONOMIC NEUROPATHY
    ROBERT EDWARD SCHMIDT; Fiscal Year: 2010
    ..signaling in sympathetic ganglia may be bypassed by the newly discovered neurotrophic effect of erythropoietin (EPO), an agent which influences the same ganglionic PI3K/Akt signaling pathway as IGF-I and is approved for patient use ..
  50. A novel mechanism of coagulation in sickle cell disease
    JULIA BRITTAIN; Fiscal Year: 2012
    ..Furthermore we show that erythropoietin (EPO), a cytokine involved in erythropoiesis, promotes the binding of the sRetic to the monocytes...
  51. CNS vulnerability to systemic chemotherapy: Causes and prevention
    Mark D Noble; Fiscal Year: 2012
    ..or preventing such damage, and is focused on analysis of the hypothesis that co-treatment with erythropoietin (EPO) reduces CNS damage caused by chemotherapy...
  52. Sonia L Bonifacio; Fiscal Year: 2016
    ..An exciting therapeutic emerging in pilot clinical trials is erythropoietin (EPO)...
  53. Kytai Truong Nguyen; Fiscal Year: 2016
    ..retinoic acid (RA), peptide or cDNA of keratinocyte growth factor (KGF) and its receptor (KGFR), or erythropoietin (EPO) and its receptor (EPOR), to be administered in combination to proportionally stimulate the alveolar epithelium, ..
  54. Erythropoiesis - Injury and Recovery
    SCOTT ALAN PESLAK; Fiscal Year: 2013
    ..the role of endogenous compounds important in the traditional stress erythroid response, such as erythropoietin (EPO), stem cell factor (SCF), and glucocorticoids, and their respective signaling pathways on the stimulation and ..
  55. Mechanisms Of Compensatory Lung Growth
    Connie C W Hsia; Fiscal Year: 2010
    ..One lung will be sampled for molecular assays to assess the expression of paracrine erythropoietin (EPO)signaling pathway via the hypoxia-inducible transcriptional factors (HIF's) and their downstream effects...
  56. James Palis; Fiscal Year: 2015
    ..mass is sustained by a robust process of cell maturation that is primarily dependent on the hormone erythropoietin (EPO)...
  57. Samuel J Danishefsky; Fiscal Year: 2016
    ..In Project 1, we expect that the synthesis of the glycoprotein hematopoietic agent, erythropoietin (EPO) in homogeneous form will be achieved...
  58. Claudia S Robertson; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Erythropoietin (EPO) is one of the most attractive agents currently being studied to improve outcome from TBI...
  59. Small Molecule Erythropoietin Receptor Agonists for the Treatment of Acute Kidney
    Juha Punnonen; Fiscal Year: 2013
    ..Previous studies support the view that, at sufficiently high doses, recombinant human (rh) erythropoietin (EPO) protects kidneys in animal models of AKI...
  60. GENE TRANSFER FOR PREVENTION OF DIABETIC NEUROPATHY
    David J Fink; Fiscal Year: 2012
    ..HSV- mediated expression of neurotrophin-3 (NT-3), vascular endothelial growth factor (VEGF), or erythropoietin (EPO) in dorsal root ganglion (DRG) in vivo prevents the progression of neuropathy in mice with streptozotocin (STZ)-..
  61. Tetrahydrobiopterin: Regulator of Endothelial Function
    ZVONIMIR KATUSIC; Fiscal Year: 2009
    ..During preliminary studies for this application we identified erythropoietin (EPO) as a novel and potent stimulator of BH4 biosynthesis in the cardiovascular system...
  62. The Use of Erythropoietin to Reprogram Oral and Craniofacial Stem Cells
    RUSSELL S contact TAICHMAN; Fiscal Year: 2010
    ..approach for partial reprogramming of somatic stem cells of the oral and craniofacial complex using erythropoietin (Epo) for cell- based therapies to heal and restore these tissues following disease or trauma...
  63. Spinal Matrix Metalloproteinases in Hyperalgesia and Allodynia
    CHRISTINA CHRISTIANSON; Fiscal Year: 2010
    ..metalloproteinase 3 (MMP-3), and associated regulatory proteins such as tissue inhibitor of metalloproteinase 1 (TIMP-1), and osteopontin in a model of inflammatory pain...
  64. Suresh C Tyagi; Fiscal Year: 2016
    ..In addition, increased levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), which enhances collagen content in subendothelial matrix (SEM), are associated with AD...
  65. Mechanisms of Reduced Fecundity in Endometriosis: A role for MMPs and TIMPs
    KATHY L TIMMS; Fiscal Year: 2012
    ..We have reported that endometriotic lesions de novo synthesize and secrete tissue inhibitor of metalloproteinase-1 (TIMP-1) and that two-fold more endometriotic TIMP-1 localizes in the ovarian follicular theca in endometriosis (Endo) ..
  66. The Role and Regulation of TIMP-1 in Lung Inflammation
    DAVID MADTES; Fiscal Year: 2005
    ..Expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) is markedly elevated in the lungs of patients with inflammatory lung diseases...
  67. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2011
    ..In October 2003, the U.S. Environmental Protection Agency (EPA) nominated four in vitro ocular toxicity test methods for evaluation as potential screening methods for eye ..
  68. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2012
    ..In October 2003, the U.S. Environmental Protection Agency (EPA) nominated four in vitro ocular toxicity test methods for evaluation as potential screening methods for eye ..
  69. IN VIVO SIGNALING OF THE ERYTHROPOIETIN RECEPTOR
    Saghi Ghaffari; Fiscal Year: 2002
    DESCRIPTION (Applicant's Description): Erythropoietin-Receptor (EPO-R) signaling is crucial for differentiation, proliferation and survival of mature erythroid progenitor cells...
  70. Nonhematopoietic Developmental Functions of EPO
    Sandra Juul; Fiscal Year: 2004
    ..Cells in contact with the developing intestinal lumen are exposed to erythropoietin (Epo) in swallowed amniotic fluid prenatally, and in human milk postnatally...
  71. John S Ikonomidis; Fiscal Year: 2015
    ..and compositional changes in the aortic ECM of old mice are mediated by age-dependent defects in collagen and MMP/TIMP gene expression...
  72. Role of Erythropoietin receptor signaling in heart
    MURAT ARCASOY; Fiscal Year: 2004
    Erythropoietin (Epo) regulates the production of red blood cells by binding to its cell surface receptor EpoR expressed on erythroid progenitor cells...
  73. Iron Delivery Via hemodialysate in ESRD
    Ajay Gupta; Fiscal Year: 2005
    Erythropoietin (EPO) is an effective therapy for anemia of end-stage renal disease (ESRD) and is used in almost all ESRD patients receiving chronic hemodialysis...
  74. 92K-GL (MMP 9) AND THE INVASIVE PHENOTYPE
    MARTIN BODDEN; Fiscal Year: 1999
    ..and subsequent degradation of substrate by MMPs are controlled by the tissue inhibitors of metalloproteinases (TIMP- 1, -2, and -3), with TIMP-l having the unique, natural ability to bind to the pro-form of 92K-GL...
  75. DNA methylation alterations in response to pesticides exposure
    Lifang Hou; Fiscal Year: 2010
    ..Although all pesticides sold in the US have passed Environmental Protection Agency (EPA) tests for carcinogenicity, exposure to pesticides have repeatedly been associated with increased human cancer ..
  76. REGULATION OF RETINAL NEOVASCULARIZATION BY TIMP3
    Bela Anand Apte; Fiscal Year: 2002
    ..Tissue Inhibitor of Metalloproteinase-3 (TIMP-3), a regulator of matrix metalloproteinases (MMPs), is deposited by retinal pigment epithelial (RPE) cells into ..
  77. NOVEL ROLE AND REGULATION OF UTERINE TIMPS
    Warren Nothnick; Fiscal Year: 2000
    The following proposal is based upon the hypothesis that TIMP-1 and TIMP-3 display specific patterns of expression in uterine tissue during the reproductive cycle, that these patterns of expression are modulated by estradiol and/or ..
  78. METALLOPROTEINASE INHIBITOR/TMP/COLLAGEN REMODELING
    MARTIN BODDEN; Fiscal Year: 1993
    The objective of the research project is to investigate the role played by TIMP, a tissue inhibitor of matrix metalloproteinases, in the regulation of collagen breakdown by fibroblasts...
  79. REGULATION OF CELL MIGRATION IN VASCULAR REMODELING
    Eric Howard; Fiscal Year: 2002
    ..One such interaction involves MT1-MMP itself, which bindings gelatinase A through a bridge with the MMP inhibitor, TIMP-2, a critical mediator of gelatinase A activation...

Patents1

  1. Process for the production of a protein
    Patent Number: EP0188312-A2; Date:1986-07-23